Tirzepatide & Ketamine: Mounjaro / Zepbound Compatibility
Mounjaro (Tirzepatide) (also: Zepbound) — Dual GIP/GLP-1 receptor agonist (weight loss / type 2 diabetes)
Verdict at Tovani Health
Fully compatible with KAP; same profile as semaglutide.
Tirzepatide and ketamine have no clinically significant interaction. Mounjaro (diabetes) and Zepbound (chronic weight management) are the same molecule with different FDA-approved indications, and both work fine alongside ketamine-assisted psychotherapy. The dual GIP and GLP-1 receptor agonism doesn't change the picture — both target receptors are in peripheral metabolic tissue, not in the central pathways ketamine acts on. The practical considerations are identical to semaglutide: GI side effects (nausea, slowed gastric emptying) can compound with session-day jitters, so we plan around dose-escalation windows and pre-medicate with ondansetron when appropriate.
If you take Mounjaro regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Mounjaro interacts with ketamine
Tirzepatide is a dual agonist of both the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor — the only dual GIP/GLP-1 agonist currently on the market. It slows gastric emptying, enhances insulin secretion, and reduces appetite, producing somewhat greater weight loss than pure GLP-1 agonists in head-to-head trials. None of these pathways overlap with ketamine's NMDA antagonism or downstream BDNF/mTOR signaling. No shared CYP metabolism. No additive cardiovascular or sedation effects to plan around.
What we do at intake
Continue your normal weekly injection schedule. Tell us: your current dose, last escalation date, whether you experience significant GI side effects, and which brand you're on (no clinical difference, but it helps us understand whether you're being treated for diabetes or weight loss, which affects how we plan around the rest of your treatment).
Bottom line
Tirzepatide and ketamine have no clinically significant interaction. Mounjaro (diabetes) and Zepbound (chronic weight management) are the same molecule with different FDA-approved indications, and both work fine alongside ketamine-assisted psychotherapy. The dual GIP and GLP-1 receptor agonism doesn't change the picture — both target receptors are in peripheral metabolic tissue, not in the central pathways ketamine acts on. The practical considerations are identical to semaglutide: GI side effects (nausea, slowed gastric emptying) can compound with session-day jitters, so we plan around dose-escalation windows and pre-medicate with ondansetron when appropriate.
Frequently Asked Questions
Is Mounjaro the same as Zepbound for KAP purposes?
Yes — identical molecule (tirzepatide). The only difference is the FDA-approved indication. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Same compatibility profile for ketamine therapy.
Does the dual GIP/GLP-1 action create unique interaction concerns vs semaglutide?
No. Both GIP and GLP-1 receptors are in peripheral metabolic tissue (pancreas, gut, fat). Neither pathway intersects with ketamine's NMDA-receptor mechanism or its CNS-level downstream effects.
My Zepbound dose was just bumped — should I delay my next session?
If the dose increase is within the past 7-14 days, often yes. Tirzepatide nausea tends to plateau by the second week of a new dose. We'd rather have you stable for the session.
Should I take my weekly tirzepatide injection on session day?
Either day works pharmacologically. Most patients prefer to inject NOT on session day to keep the day's variables minimal — but we don't require it.
Zepbound's label had a suicidal-ideation warning. Should I be worried about adding ketamine?
The warning was an FDA class rule for chronic weight management drugs that act on the CNS — Saxenda, Wegovy, and Zepbound all carried it. The January 2026 FDA action removed the warning after a comprehensive review of 91 trials found no evidence of increased suicidality. The combination with ketamine has no special concern beyond what's true for any patient starting ketamine therapy.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Mounjaro (Tirzepatide) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications. Voelker R.. JAMA. 2026. PMID: 41615669
January 2026 FDA action explicitly named Zepbound among the three weight-loss GLP-1s having the SI warning removed after the 91-trial meta-analysis showed no causal link.
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs. et al.. International Journal of Clinical Pharmacy. 2026. PMID: 41739406
Class-wide pharmacovigilance signal analysis covering tirzepatide alongside semaglutide and liraglutide.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk. et al.. Biological Psychiatry. 2026. PMID: 42069105
Synthesis of the evidence on GLP-1 RAs and mood — concludes no causal link at the population level.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Comprehensive ketamine PK/PD review — establishes the metabolic pathways tirzepatide doesn't share.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 27, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.